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Introduction
Reovirus type 3 Dearing (RT3D, Reolysin®; Oncolytics Biotech, Inc) is a naturally occurring non-pathogenic, double-stranded RNA virus isolated from the respiratory and gastrointestinal tracts of humans (1) . Reovirus infection is essentially ubiquitous with up to 100% seropositivity rates in healthy adults (2) .
Ras pathway activation, either through Ras mutation or overexpression/mutational activation of epidermal growth factor receptor (EGFR), has been reported to be a prerequisite for reovirus sensitivity (3, 4) .
Reovirus has been shown to exert significant anti-tumour effects in pre-clinical in vitro and in vivo studies. In addition, reovirus can activate both innate and adaptive anti-tumour immune responses against murine and human tumors (5, 6 ).
Both intralesional (7) and systemic (8, 9) administration of RT3D have very favourable toxicity profiles with preliminary evidence of anti-tumour activity.
However, responses to RT3D monotherapy are modest and short-lived and this has led to clinical trials testing combinations of RT3D with either radiotherapy (10) or single agent chemotherapy (11, 12). These studies have confirmed feasibility and safety with a number of patients showing disease responses. When RT3D was administered intravenously (i.v.) in a phase I study in thirty-three heavily pre-treated patients with solid tumors, no doselimiting toxicity (DLT) was observed up to the dose of 3 x 10 10 TCID 50 /day for 5 consecutive days repeated every four weeks. Toxicity was mild including fever, fatigue and headache (9). Dose escalation did not proceed above the 3
x 10 10 TCID 50 /day level because this was the manufacturing limit of RT3D at that time. As a result, none of the subsequent studies in which i.v. RT3D has been combined with cytotoxic chemotherapy has exceeded that dose limit. In the combination of RT3D and gemcitabine, three subjects experienced DLT 
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Replication-competent virus was present only in post-treatment biopsies (9).
In addition, we recently confirmed virus delivery to metastatic cancer deposits by immunohistochemistry in patients treated with RT3D and docetaxel [11] .
Preclinical in vitro and in vivo combinations of RT3D with platin-and/or taxane-based chemotherapy have been shown to be highly synergistic in melanoma(13), prostate(14) and non-small cell lung cancer (15) through enhanced viral replication and apoptosis. Therefore, we hypothesized that combining RT3D with carboplatin/paclitaxel combination chemotherapy would be an attractive approach for clinical testing. Here, we report a phase I trial of carboplatin/paclitaxel and reovirus in patients with relapsed/metastatic cancers. The promising initial results in patients with tumours of the head and neck (including squamous and non-squamous histologies) led to a phase II expansion exclusively in this indication. As a result of the phase I and II experience, a phase III trial has now opened for taxane-naive patients with relapsed/metastatic squamous cell cancer of the head and neck (SCCHN) that has progressed within 6 months of first-line palliative platin-based chemotherapy.
Research. 
Treatment plan
An initial dose-escalation phase I study defined the safety profile of RT3D combined with paclitaxel/carboplatin and provided a recommended dose for phase II evaluation (Figure 1) . At the end of phase I dose-escalation, an expansion cohort of 5 patients was recruited at the 3 x 10 10 TCID 50 dose level.
Research. Escalation was allowed when two patients had received two cycles of therapy on the previous dose level. If one of three patients in a cohort were to experience DLT in cycle 1, three more patients would be added to that cohort.
If two or more patients in a cohort were to experience DLT in cycle 1, the previous lower dose would be the MTD and the recommended phase II dose (RP2D). DLT was defined as any of the following events occurring in the first cycle that were determined to be possibly or probably related to combination 
Effectiveness evaluation
Response was assessed by Response Evaluation Criteria in Solid Tumours (RECIST) (16) or by clinical evaluation where applicable. All patients were clinically evaluated on a weekly basis while on treatment and radiologically every three cycles (cycle 3, 6, and 8). Per protocol, effectiveness was evaluated in patients who received at least two cycles of combination treatment.
Laboratory analyses

Analysis of viral shedding by reverse transcription-PCR:
Patients in the phase I study had biological samples (blood, urine, feces, sputum) collected for viral detection before reovirus infusion, 4 hours after the day 5 dose, on day 15 of cycles 1 and 2 and at follow-up visits. Sample processing and reverse transcription-PCR (RT-PCR) methods were as previously described(9).
Detection of neutralizing anti-reoviral antibodies (NARA):
A modified neutralizing antibody assay was used as previously described (18) . The NARA titer of serum samples was expressed as the last dilution causing <80% cell killing. NARA titers were measured at baseline and weekly for the first two cycles of treatment and at follow-up visits for all patients in phase I. Table 1 .
Treatment-related toxicity
Treatment was well tolerated in both phase I and II studies. The commonest treatment-related toxicities included blood cytopenias, nausea and vomiting, fatigue, diarrhea, oral candidiasis/stomatitis, alopecia, muscle pain, fever and chills, influenza-like symptoms, rash and flushing. Grade 3/4 hematologic toxicities were neutropenia (16.1%), asymptomatic lymphopenia (6.5%) and anemia (3.2%). Only one episode of grade 4 neutropenia was complicated with sepsis. Non-haematologic grade 3/4 toxicities included fever following reovirus infusion (9.7%), myalgia (6.5%), diarrhea (3.2%), nausea (3.2%), vomiting (3.2%) and hypotension (3.2%). There was no relationship between reovirus dose level and incidence or grade of symptoms. Adverse events and treatment-related toxicities are detailed in Table 2 .
The mean number of cycles administered was 4.8 (range 1-8), but this fact must be considered in light of the fact that responding patients who reached 8 cycles of treatment had their therapy discontinued per protocol. Reovirus was given at full dose in all infusions without dose reduction. Eight patients required dose reductions of carboplatin and paclitaxel: 2 patients required a 10% dose reduction; 5 patients required a 25% dose reduction and 1 patient required a 50% dose reduction.
Effectiveness
A total of 31 patients were included in the study. 
12 treatment and three discontinued treatment after the first cycle due to a serious adverse event (sepsis (n=1), abdominal pain and diarrhea (n=1), urinary tract infection (n=1)). Table 3 lists the effectiveness data by primary tumour type. One patient had a complete response (3.8%), 6 patients (23.1%) had partial response, 2 patients (7.7%) had major clinical responses evaluated in radiation pretreated lesions which are not evaluable by RECIST, 9 patients (34.6%) had stable disease and 8 patients (30.8%) had disease progression. Table 4 analysis, median overall survival was estimated at 7.1 (CI 4.2-11.5) months (mean 8.9 (SD +1.4) months) (Fig 2K) .
All 14 patients with squamous cell cancer of the head and neck had received prior platinum-based chemotherapy and in 12 of those patients it had been used as palliative treatment for relapsed disease. In the other two cases, disease had progressed shortly after platin-based chemoradiotherapy. The responses of all of those patients to study medication are detailed in Table 4 .
Three patients (2 nasopharyngeal cancer, 1 squamous cell skin cancer) had received prior taxane-based palliative chemotherapy. As the first patient in the phase II component had a partial response, the two question Gehan design was satisfied, indicating the combination is likely to be effective in at least 20% of patients or more with a rejection error of 5% or 0.05.
Viral biodistribution
The presence of viral RNA in serum, urine, stool and sputum samples was tested in all patients participating in the phase I study. All pre-treatment and post-treatment samples were negative in 10 patients and only 3 patients had Figure 1) . No patient had evidence of sustained viral excretion but one patient had positive signals in the urine at day 5 in the first two cycles.
NARA response
All patients in phase I had evaluable samples for NARA expressed as fold increase over pre-treatment samples. All patients showed an increase in NARA titer with a range of 27-to 729-fold at cycle 1, day 15 and 27-to 2187-fold at peak (Supplementary Figure 2) . The maximum NARA level in patients treated with paclitaxel/carboplatin and reovirus was reached later than in previous studies of single-agent reovirus. Representative examples of the neutralization curves from patients in each cohort are shown (Supplementary Figure 3) .
Paclitaxel and Carboplatin pharmacokinetics
The effect of reovirus on paclitaxel and carboplatin pharmacokinetics was 
Discussion
We have previously shown that intravenous reovirus is safe, with the main toxicities being grade 2/3 flu-like illness and uncomplicated lymphopenia(8, 9).
Furthermore, intravenous reovirus combined with gemcitabine was well tolerated with the expected toxicities from each drug, apart from asymptomatic, reversible grade 3 transaminitis and asymptomatic grade 3 elevation of troponin I(12). Similarly, reovirus has been combined with docetaxel in a phase I study with no toxicities other than those associated with either single agent(11). The current study is the first to add virotherapy to a combination chemotherapy regimen with a wide spectrum of activity.
Treatment was well tolerated and reovirus MTD was not reached. The rate of myelosuppression (16.1%) was not greater than expected and there was only one episode of sepsis. Similarly, the occurrence of fever, flu-like illness, musculoskeletal pain, gastrointestinal disorders, fatigue and alopecia were entirely consistent with those seen with chemotherapy alone. As with our previous studies, viral shedding was observed infrequently, suggesting that the normal rapid viral clearance from the circulation is unaffected by concomitant combination chemotherapy. These data provided the basis for out-patient treatment delivery in the phase II study. Importantly, escalating reovirus doses had no effect on the pharmacokinetics of paclitaxel or carboplatin.
As expected, NARA titers increased in all patients. However, the kinetics of NARA development were altered when compared with data for patients treated with single agent reovirus(9, 18). Therefore, the maximum NARA titer was reached later in the treatment cycles. The role of neutralising anti-viral antibodies has been debated extensively, but there is a general perception that they may represent both an obstacle to viral delivery and a protection against virus-mediated systemic toxicity (19) . Slower development of total titers may have beneficial effects on tumour seeding with virus without compromising safety. Our recent experience with reovirus combined with gemcitabine has also shown that systemic chemotherapy may be able to modulate anti-reoviral antibody responses in patients(12). This area is certainly worthy of further evaluation in future studies. The phase II study was specifically designed to evaluate the antitumour activity of carboplatin/paclitaxel plus reovirus in patients with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. HNC patients who were recruited were heavily pretreated with prior surgery, radiotherapy/chemoradiotherapy, targeted therapies and most had received at least one line of palliative chemotherapy. For six patients, the combination of carboplatin and paclitaxel with R3D represented third-or fourth-line treatment.
All but four HNC patients (83%) had received platinum-based therapy within 6 months of study entry) and three patients had received both platinum and taxane therapy. A retrospective analysis of platinum-refractory head and neck squamous cell cancer reported a 2.6% objective response rate to second-line treatment (20) . Little improvement in terms of response rate was observed when this subgroup was treated with chemotherapy and cetuximab, with a response rate of 10% and a disease control rate of 53% (21 
